SRR8613793
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.350
- SPERMATOGENESIS+0.150
- ESTROGEN_RESPONSE_EARLY+0.080
- ESTROGEN_RESPONSE_LATE+0.070
- ADIPOGENESIS+0.040
- MYC_TARGETS_V2+0.030
- MYOGENESIS+0.030
- KRAS_SIGNALING_DN+0.020
- CHOLESTEROL_HOMEOSTASIS+0.000
- OXIDATIVE_PHOSPHORYLATION-0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.520
- TNFA_SIGNALING_VIA_NFKB-0.440
- INFLAMMATORY_RESPONSE-0.430
- IL6_JAK_STAT3_SIGNALING-0.420
- COMPLEMENT-0.380
- E2F_TARGETS-0.350
- APOPTOSIS-0.340
- IL2_STAT5_SIGNALING-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617918 | — | B | 0.880 |
| 2 | SRR10899984 | — | — | 0.863 |
| 3 | C3L-03726 | — | cohortA2 | 0.861 |
| 4 | MNG199 | — | — | 0.859 |
| 5 | c8b9a438-4194-4243-a738-4e0bd4184f19 | — | — | 0.856 |
| 6 | TCGA-E9-A245-01A-22R-A16F-07 | — | B | 0.852 |
| 7 | SRR35579800 | — | B | 0.851 |
| 8 | MNG760 | — | — | 0.849 |
| 9 | SRR1516072 | — | — | 0.848 |
| 10 | SRR1343841 | GTEX | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.030 | Idelalisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |